DCC-2618

Cat. No.: HY-112306  
CAS No.: 1442472-39-0  
Molecular Formula: C₂₄H₂₁BrFN₅O₂  
Molecular Weight: 510.36  
Target: c-Kit; PDGFR  
Pathway: Protein Tyrosine Kinase/RTK  
Storage: Powder  
-20°C 3 years  
4°C 2 years  
In solvent  
-80°C 6 months  
-20°C 1 month

Solvent & Solubility

<table>
<thead>
<tr>
<th>In Vitro</th>
<th>DMSO: ≥ 62.5 mg/mL (122.46 mM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preparing Stock Solutions</td>
<td>DMSO : ≥ 62.5 mg/mL (122.46 mM)</td>
</tr>
<tr>
<td></td>
<td>* &quot;≥&quot; means soluble, but saturation unknown.</td>
</tr>
<tr>
<td></td>
<td><strong>Solvent</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Concentration</strong></td>
</tr>
<tr>
<td>1 mM</td>
<td>1.9594 mL</td>
</tr>
<tr>
<td>5 mM</td>
<td>0.3919 mL</td>
</tr>
<tr>
<td>10 mM</td>
<td>0.1959 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (4.08 mM); Clear solution

BIOLOGICAL ACTIVITY

Description
DCC-2618 is a pan-KIT and PDGFRA inhibitor, and has antitumor activity.

IC₅₀ & Target
PDGFRA; KIT

In Vitro
DCC-2618 is a pan-KIT and PDGFRA inhibitor, shows cytotoxic activity against gastrointestinal stromal tumors[1]. DCC-2618 suppresses phosphorylation of KIT and decreases the expression of phosphophorylated (p)STAT5, pAKT and pERK1/2 in neoplastic mast cells. DCC-2618 inhibits the growth of ROSAKIT K509I cells with an IC₅₀ of 34 ± 10 nM, and also induces apoptosis in these cells. DCC-2618 (0.1-1.0 μM) inhibits IgE-dependent histamine release from basophils and spontaneous tryptase release from neoplastic mast cells, and also counteracts growth and survival of leukemic monocytes and blast cells at 0.01-5 μM[2].
REFERENCES


Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA